Loading...

KORU Medical Systems, Inc.

KRMDNASDAQ
Healthcare
Medical - Instruments & Supplies
$4.38
$0.27(6.57%)

KORU Medical Systems, Inc. (KRMD) Financial Performance & Income Statement Overview

Explore the financials of KORU Medical Systems, Inc. (KRMD), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
17.98%
17.98%
Operating Income Growth
37.23%
37.23%
Net Income Growth
55.85%
55.85%
Operating Cash Flow Growth
93.47%
93.47%
Operating Margin
-12.57%
12.57%
Gross Margin
63.15%
63.15%
Net Profit Margin
-12.25%
12.25%
ROE
-26.79%
26.79%
ROIC
-23.80%
23.80%

KORU Medical Systems, Inc. (KRMD) Income Statement & Financial Overview

Analyze KORU Medical Systems, Inc.’s KRMD earnings with segmented quarterly and yearly financial statement figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$9.64M$8.84M$8.18M$8.43M
Cost of Revenue$3.59M$3.28M$2.99M$2.95M
Gross Profit$6.05M$5.56M$5.19M$5.48M
Gross Profit Ratio$0.63$0.63$0.63$0.65
R&D Expenses$1.11M$1.11M$1.53M$1.13M
SG&A Expenses$5.96M$5.83M$5.13M$5.32M
Operating Expenses$7.07M$7.15M$6.89M$6.45M
Total Costs & Expenses$10.66M$9.99M$9.88M$9.62M
Interest Income$0.00$80459.00$112995.00$214000.00
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$217357.00$211454.00$227786.00$217864.00
EBITDA-$810291.00-$1.38M-$1.48M-$974170.00
EBITDA Ratio-$0.08-$0.16-$0.18-$0.12
Operating Income-$1.03M-$1.59M-$1.70M-$1.19M
Operating Income Ratio-$0.11-$0.18-$0.21-$0.14
Other Income/Expenses (Net)-$138589.00$31283.00$122480.00$203319.00
Income Before Tax-$1.17M-$1.56M-$1.58M-$988715.00
Income Before Tax Ratio-$0.12-$0.18-$0.19-$0.12
Income Tax Expense$0.00$2893.00$0.00$0.00
Net Income-$1.17M-$1.56M-$1.58M-$988715.00
Net Income Ratio-$0.12-$0.18-$0.19-$0.12
EPS-$0.03-$0.03-$0.03-$0.02
Diluted EPS-$0.03-$0.03-$0.03-$0.02
Weighted Avg Shares Outstanding$45.98M$45.91M$45.85M$45.81M
Weighted Avg Shares Outstanding (Diluted)$45.98M$45.91M$45.85M$45.81M

Over the past four quarters, KORU Medical Systems, Inc. demonstrated steady revenue growth, increasing from $8.43M in Q2 2024 to $9.64M in Q1 2025. Operating income reached -$1.03M in Q1 2025, maintaining a consistent -11% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$810291.00, reflecting operational efficiency. Net income rose to -$1.17M, with EPS at -$0.03. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;